Public company intelligence preview
PHIO PHARMACEUTICALS CORP
23 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $289748.09 average total compensation across covered insiders.
Governance movement
Public aggregate: 4 governance events in the last year.
Institutional ownership
Public aggregate: 17 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
PHIO Pharmaceuticals Corp. is a Healthcare sector, Biotechnology company focused on developing cancer immunotherapies through its proprietary INTASYL siRNA gene-silencing platform. The company is still clinical-stage and has no commercial product revenue, with its lead program PH-762 being tested in a Phase 1b trial for skin cancers such as cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. Management has highlighted encouraging early response data and no dose-limiting toxicities so far, but the business remains dependent on clinical progress, regulatory milestones, and outside manufacturing partners.
Executive Compensation Practices
Executive compensation at PHIO is likely driven more by development-stage milestones than by revenue or earnings, since the company has no product sales and continues to post operating losses. In a Biotechnology company like this, pay packages often emphasize stock-based compensation, RSUs, option grants, and retention awards to align management with trial success, FDA interactions, and long-term shareholder value. The filing summaries show rising employee compensation and stock-based compensation, which suggests equity awards are an important part of total compensation and may be used to conserve cash while incentivizing progress on PH-762 and future financing execution.
Insider Trading Considerations
Insider trading activity in a clinical-stage biotech like PHIO is often closely tied to trial readouts, FDA guidance, financing events, and manufacturing updates, all of which can materially move the stock. Because the company has limited cash and depends on periodic capital raises, insiders may be more active around offering windows, warrant exercises, or financing-related dilution events. Researchers and traders should watch for trades around milestones such as final Phase 1b data, FDA next-step guidance, and manufacturing or IP announcements, since these events can have outsized effects on a small-cap biotech’s valuation and liquidity.
Unlock the full PHIO insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.